Next Article in Journal
Natural History and Management of Small Renal Masses
Previous Article in Journal
Preface
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue s1
10.3747/co.v16i0.407
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

State-of-the-Art Treatment of Metastatic Renal Cell Carcinoma

by
D. Y. C. Heng
1 and
C. Kollmannsberger
2,*
1
Medical Oncology, Tom Baker Cancer Center, Calgary, AB, Canada
2
Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(s1), 16-23; https://doi.org/10.3747/co.v16i0.407
Submission received: 5 February 2009 / Revised: 7 March 2009 / Accepted: 14 April 2009 / Published: 1 May 2009

Abstract

Targeted therapy has greatly changed the way in which metastatic renal cell carcinoma (RCC) is treated. Agents that inhibit the vascular endothelial growth factor and mammalian target of rapamycin pathways that otherwise lead to angiogenesis have now become the standard of care. Much research into the sequence and combination of these agents is ongoing, and new anti-angiogenic agents are being developed. This overview covers the standard treatment of metastatic RCC with targeted therapy, immunotherapy, and surgery. Future directions and ongoing clinical trials are also discussed.
Keywords: renal cell carcinoma; vascular endothelial growth factor; platelet-derived growth factor; mammalian target of rapamycin inhibitors; sunitinib; sorafenib; temsirolimus renal cell carcinoma; vascular endothelial growth factor; platelet-derived growth factor; mammalian target of rapamycin inhibitors; sunitinib; sorafenib; temsirolimus

Share and Cite

MDPI and ACS Style

Heng, D.Y.C.; Kollmannsberger, C. State-of-the-Art Treatment of Metastatic Renal Cell Carcinoma. Curr. Oncol. 2009, 16, 16-23. https://doi.org/10.3747/co.v16i0.407

AMA Style

Heng DYC, Kollmannsberger C. State-of-the-Art Treatment of Metastatic Renal Cell Carcinoma. Current Oncology. 2009; 16(s1):16-23. https://doi.org/10.3747/co.v16i0.407

Chicago/Turabian Style

Heng, D. Y. C., and C. Kollmannsberger. 2009. "State-of-the-Art Treatment of Metastatic Renal Cell Carcinoma" Current Oncology 16, no. s1: 16-23. https://doi.org/10.3747/co.v16i0.407

APA Style

Heng, D. Y. C., & Kollmannsberger, C. (2009). State-of-the-Art Treatment of Metastatic Renal Cell Carcinoma. Current Oncology, 16(s1), 16-23. https://doi.org/10.3747/co.v16i0.407

Article Metrics

Back to TopTop